| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.6 | 20.1 |
| Profit before tax | -9.6 | 1.8 |
| Net income | -9.9 | 1.5 |
| EPS (diluted, $ a share) | $-0.68 | $0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -91.9% |
|---|
10-Q filed with the SEC, NASDAQ: SCTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Scribe Therapeutics, Inc.: key numbers
- Share price
- $15.37Close, Nov 16
- Market cap
- $291M
- Shares outstanding
- 18.93MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Scribe Therapeutics, Inc.
All →Scribe Therapeutics Financial Results
Scribe Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $174.2 million following its successful upsized IPO. The company is advancing its Phase 1 clinical trial for STX-1150, an epigenetic silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027.
“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients.”
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics